Capital Flow Monitor · Sponsors · CIK 1815337
Triana Biomedicines, Inc.
1050 WALTHAM STREET, LEXINGTON, MA, 02421 · 781-317-4414
Pharmaceuticals · Corporation· inc. DELAWARE true
Fit score
—
Offering
$120.1M
Sold
$120.1M
% sold
100.0%
Investors
20
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2025-12-04 | D ·current | 506(b) | $120.1M | $120.1M | 100.0% | 20 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Patrick Trojer — Executive Officer / Director, Lexington, MA
-
David Grayzel — Director, Lexington, MA
1 other raise
- Affinia Therapeutics Inc. $13.3M of $45.0M · 29.5%
-
Joshua Resnick — Director, Waltham, MA
2 other raises
- Jericho Capital Special Opportunities Ltd $180.1M of —
- Jericho Capital International Ltd. $1.21B of —
-
Jigar Raythatha — Director, Waltham, MA
1 other raise
- Third Rock Ventures VII, L.P. $0 of $750.0M · 0.0%
-
Christopher O'Donnell — Director, Lexington, MA
1 other raise
- MindImmune Therapeutics, Inc. $15.2M of $17.0M · 89.4%
-
Shelley Chu — Director, Lexington, MA
2 other raises
- Odyssey Therapeutics, Inc. $214.0M of $214.0M · 100.0%
- Enlaza Therapeutics, Inc. $15.0M of $15.0M · 100.0%
- Lorence Kim — Director, Lexington, MA
-
Andrew Hedin — Director, Lexington, MA
1 other raise
- Converge Bio Inc. $25.0M of $25.0M · 100.0%
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.